Quizartinib is an orally administered, highly potent and selective next-generation FLT3 inhibitor currently in phase 3 development in patients with FLT3–ITD-mutated AML (QuANTUM-R: NCT02039726; QuANTUM-First: NCT02668653). Here, FLT3 is linked to acute myeloid leukemia.